Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ABIO ARCA biopharma, Inc. daily Stock Chart
ABIO [NASD]
ARCA biopharma, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-8.58 Insider Own0.83% Shs Outstand1.46M Perf Week0.73%
Market Cap10.10M Forward P/E- EPS next Y-15.42 Insider Trans0.00% Shs Float1.45M Perf Month10.90%
Income-6.90M PEG- EPS next Q-1.86 Inst Own9.10% Short Float3.62% Perf Quarter19.10%
Sales- P/S- EPS this Y67.70% Inst Trans- Short Ratio0.07 Perf Half Y-6.23%
Book/sh8.17 P/B0.85 EPS next Y-61.10% ROA-80.90% Target Price17.00 Perf Year-33.64%
Cash/sh- P/C- EPS next 5Y- ROE-92.10% 52W Range4.72 - 23.04 Perf YTD15.28%
Dividend- P/FCF- EPS past 5Y39.80% ROI- 52W High-69.97% Beta1.80
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low46.46% ATR0.48
Employees15 Current Ratio6.60 Sales Q/Q- Oper. Margin- RSI (14)46.94 Volatility5.90% 7.38%
OptionableNo Debt/Eq0.00 EPS Q/Q48.60% Profit Margin- Rel Volume0.02 Prev Close7.20
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout- Avg Volume804.01K Price6.92
Recom- SMA200.31% SMA50-11.17% SMA200-17.02% Volume17,842 Change-3.89%
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Jun-04-19 07:09AM  One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price Simply Wall St.
May-13-19 09:00AM  ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure GlobeNewswire -10.00%
May-08-19 04:30PM  ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +20.03%
May-01-19 08:30AM  GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure GlobeNewswire +98.64%
Apr-23-19 08:30AM  ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial GlobeNewswire
Mar-18-19 08:30AM  Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology GlobeNewswire
Mar-06-19 08:00AM  Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine GlobeNewswire
Feb-27-19 04:15PM  ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-20-19 07:30AM  ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug GlobeNewswire +31.27%
Jan-16-19 08:30AM  Zosano Appoints Linda Grais M.D., J.D. to Board of Directors GlobeNewswire
Dec-26-18 11:47AM  ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling Simply Wall St. -7.06%
Dec-20-18 04:01PM  ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire -25.26%
Nov-14-18 04:30PM  ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -6.94%
Nov-12-18 08:30AM  GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions GlobeNewswire
Nov-05-18 08:30AM  ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions GlobeNewswire +13.17%
Oct-10-18 04:16PM  Westminster biotech company receives second extension on delisting notice from Nasdaq American City Business Journals -5.43%
Oct-02-18 08:00AM  Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics ACCESSWIRE -35.29%
Sep-18-18 08:30AM  ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire
Aug-09-18 04:15PM  ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 09:45AM  Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018 ACCESSWIRE
Jul-31-18 12:15PM  3 Biotech Stocks in Focus on Tuesday ACCESSWIRE
08:30AM  ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation GlobeNewswire
08:10AM  Todays Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma ACCESSWIRE
Jun-19-18 07:05AM  Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
May-29-18 08:30AM  GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire -15.87%
May-11-18 08:20AM  Todays Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma ACCESSWIRE -9.09%
May-10-18 08:30AM  ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire +14.37%
07:15AM  Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-08-18 04:15PM  ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update GlobeNewswire
Apr-23-18 08:30AM  ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement GlobeNewswire
Apr-03-18 07:20AM  Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease ACCESSWIRE -5.17%
Mar-22-18 04:30PM  ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Feb-27-18 03:00PM  Heres Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today SmarterAnalyst +41.11%
Feb-26-18 02:18PM  ARCA biopharma And ObsEva Just Put Out Clinical Trial Data Market Exclusive -71.88%
08:00AM  ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial GlobeNewswire
Jan-23-18 05:13PM  One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO) Simply Wall St.
Jan-08-18 08:30AM  ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial GlobeNewswire +10.00%
Jan-02-18 05:09PM  What You Must Know About ARCA biopharma Incs (NASDAQ:ABIO) Major Investors Simply Wall St.
Dec-08-17 06:13PM  Interested In Healthcare? Why ARCA biopharma Inc (ABIO) May Be The Entry Point Simply Wall St.
Nov-30-17 02:25PM  How Much is ARCA biopharma Incs (ABIO) CEO Getting Paid? Simply Wall St.
Nov-20-17 08:05AM  ARCA Biopharma, European Patent for Gencaro and Q3 Review ACCESSWIRE
Nov-17-17 08:10AM  Todays Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics ACCESSWIRE
Nov-16-17 08:30AM  ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting GlobeNewswire +20.83%
Nov-09-17 04:05PM  ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Oct-23-17 08:16PM  ARCA biopharma Inc (ABIO): How Does It Impact Your Portfolio? Simply Wall St. +8.00%
Sep-21-17 08:30AM  ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference GlobeNewswire
Aug-16-17 08:30AM  ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial GlobeNewswire
Aug-09-17 04:30PM  ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis GlobeNewswire -6.85%
Aug-03-17 04:15PM  ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire +7.89%
Jun-20-17 08:30AM  ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis DSMB Recommendation Anticipated in August 2017 GlobeNewswire
May-15-17 08:30AM  ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Apr-26-17 08:30AM  ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial Business Wire
Apr-18-17 08:30AM  ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference Business Wire
Mar-25-17 01:04PM  ARCA BIOPHARMA, INC. Financials
Mar-21-17 04:46PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update Business Wire
04:10PM  ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
Mar-06-17 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-01-17 04:47PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 08:46AM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:30AM  Anders Hove, MD Joins ARCA biopharma Board of Directors Business Wire
Jan-18-17 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Jan-11-17 04:54PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Jan-04-17 08:30AM  ARCA biopharma to Present at Biotech Showcase 2017 Business Wire
Dec-20-16 02:26PM  Hedge Funds Arent Crazy About A. M. Castle & Co (CASL) Anymore at Insider Monkey
Nov-15-16 08:30AM  StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development PR Newswire
Nov-14-16 05:19PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
05:08PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
04:15PM  ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update Business Wire
Oct-06-16 04:07PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Oct-04-16 08:30AM  ARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference Business Wire
Sep-13-16 09:00AM  ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award Business Wire
Aug-18-16 04:16PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  ARCA biopharma Announces 100th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Aug-09-16 04:37PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update Business Wire
Aug-03-16 01:37AM  Albioma :ABIO-FR: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016
Jun-13-16 05:01PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o
May-11-16 04:57PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:49PM  ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
04:30PM  ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update Business Wire
Apr-18-16 04:31PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-17-16 04:44PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM  ARCA biopharma Announces Fiscal Year 2015 Financial Results and Provides Business Update Business Wire
04:14PM  ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
02:25PM  Bearish case for Valeant
Mar-07-16 04:32PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Feb-16-16 04:41PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-12-16 08:46AM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient Business Wire
Dec-08-15 09:00AM  Applying Lessons from KBIO Accesswire
Nov-30-15 09:38AM  2 Micro-Cap Opportunities in Atrial Fibrillation Accesswire
Nov-23-15 03:07PM  Biotechs Under 20 Dollars Poised to Breakout Accesswire
Nov-19-15 08:30AM  ARCA biopharma to Present at the 27th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-18-15 09:42AM  2 Important Takeaways from ARCA Biopharma's Q3 Results Accesswire
Nov-12-15 04:43PM  ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic HF. It has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
open in yahoo | open in reuters | open in google